167 related articles for article (PubMed ID: 29476592)
1. Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.
Tagad HD; Debnath S; Clausse V; Saha M; Mazur SJ; Appella E; Appella DH
ChemMedChem; 2018 May; 13(9):894-901. PubMed ID: 29476592
[TBL] [Abstract][Full Text] [Related]
2. Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase.
Robello M; Zheng H; Saha M; George Rosenker KM; Debnath S; Kumar JP; Tagad HD; Mazur SJ; Appella E; Appella DH
Eur J Med Chem; 2022 Dec; 243():114763. PubMed ID: 36179402
[TBL] [Abstract][Full Text] [Related]
3. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
5. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
6. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
Yamaguchi H; Durell SR; Feng H; Bai Y; Anderson CW; Appella E
Biochemistry; 2006 Nov; 45(44):13193-202. PubMed ID: 17073441
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
8. Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.
Gilmartin AG; Faitg TH; Richter M; Groy A; Seefeld MA; Darcy MG; Peng X; Federowicz K; Yang J; Zhang SY; Minthorn E; Jaworski JP; Schaber M; Martens S; McNulty DE; Sinnamon RH; Zhang H; Kirkpatrick RB; Nevins N; Cui G; Pietrak B; Diaz E; Jones A; Brandt M; Schwartz B; Heerding DA; Kumar R
Nat Chem Biol; 2014 Mar; 10(3):181-7. PubMed ID: 24390428
[TBL] [Abstract][Full Text] [Related]
9. The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.
Yamaguchi H; Durell SR; Chatterjee DK; Anderson CW; Appella E
Biochemistry; 2007 Nov; 46(44):12594-603. PubMed ID: 17939684
[TBL] [Abstract][Full Text] [Related]
10. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J
Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432
[TBL] [Abstract][Full Text] [Related]
12. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation.
Takekawa M; Adachi M; Nakahata A; Nakayama I; Itoh F; Tsukuda H; Taya Y; Imai K
EMBO J; 2000 Dec; 19(23):6517-26. PubMed ID: 11101524
[TBL] [Abstract][Full Text] [Related]
13. Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
Clausse V; Tao D; Debnath S; Fang Y; Tagad HD; Wang Y; Sun H; LeClair CA; Mazur SJ; Lane K; Shi ZD; Vasalatiy O; Eells R; Baker LK; Henderson MJ; Webb MR; Shen M; Hall MD; Appella E; Appella DH; Coussens NP
J Biol Chem; 2019 Nov; 294(46):17654-17668. PubMed ID: 31481464
[TBL] [Abstract][Full Text] [Related]
14. WIP1 dephosphorylation of p27
Choi BK; Fujiwara K; Dayaram T; Darlington Y; Dickerson J; Goodell MA; Donehower LA
Cell Cycle; 2020 Feb; 19(4):479-491. PubMed ID: 31959038
[TBL] [Abstract][Full Text] [Related]
15. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
[TBL] [Abstract][Full Text] [Related]
16. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
Hayashi R; Tanoue K; Durell SR; Chatterjee DK; Jenkins LM; Appella DH; Appella E
Biochemistry; 2011 May; 50(21):4537-49. PubMed ID: 21528848
[TBL] [Abstract][Full Text] [Related]
17. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Long X; Lin XJ
J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
[TBL] [Abstract][Full Text] [Related]
18. The Regulation of Trophoblastic p53 Homeostasis by the p38-Wip1 Feedback Loop is Disturbed in Placentas from Pregnancies Complicated by Preeclampsia.
Tan B; Tong C; Yuan Y; Xu P; Wen L; Zhang C; Zheng Y; Lin L; Zhu F; Gui S; Wang L; Gao R; Li J; Qi H; Baker PN
Cell Physiol Biochem; 2019; 52(2):315-335. PubMed ID: 30816677
[TBL] [Abstract][Full Text] [Related]
19. The role of PPM1D in cancer and advances in studies of its inhibitors.
Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y
Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900
[TBL] [Abstract][Full Text] [Related]
20. WIP1 phosphatase at the crossroads of cancer and aging.
Le Guezennec X; Bulavin DV
Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
